[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tobacco\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tobacco":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,81,111,141,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100638499","a-study-to-determine-the-effects-of-ends-flavor-availability-on-abstinence-within-smokers-100638499",false,"NCT07598136","A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers","A Randomized Controlled Trial to Determine the Effect of Flavor Availability on Smoking Abstinence With an Electronic Nicotine Delivery System in Primary Combustible Cigarette Smokers","Inclusion Criteria:\n\n* Able to read, understand, and are willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.\n* Generally healthy male or female, between 21 and 65 years of age, inclusive, at the time of consent.\n* All female (assigned at birth) and those who identify as \"intersex\" or \"unknown candidate\" participants who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant.\n* Currently smoke at least 5 CC on smoking days in the past 30 days.\n* Smoke CC on 15 or more of the past 30 days.\n* Smoked at least 100 factory-made CC in their lifetime prior to the SEV.\n* Indicate a willingness to use ENDS.\n* Own and regularly use a smartphone (iOS or Android) with internet access to download a study application to access surveys and the capability to receive notifications.\n* Agree to participate in the study and to abide by the study restrictions and requirements, as described in the ICF.\n\nExclusion Criteria:\n\n* Female participants who are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.\n* Male participants who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or refrain from donating sperm from the signing of the ICF until the end of the study, unless they have undergone a vasectomy or are abstinent from heterosexual intercourse, or their female partner was not able to bear children.\n* Female participants who self-report not using adequate methods to prevent pregnancy.\n* Persons with pacemakers or other embedded electronic medical devices fitted.\n* Participants who self-report having an unstable heart condition, severe hypertension or diabetes.\n* Persons who self-report they are allergic\u002Fsensitive to cosmetics or fragrances, or any ingredient listed in commercial e-cigarette products.\n* Participants who self-report poor physical or mental health.\n* Participants who have used ENDS, nicotine pouch, smokeless tobacco (i.e., chewing tobacco, snus, or snuff) products, heated tobacco products, other combustible products and other oral nicotine products (tablets, gums and lozenges) on 5 or more days in the past 30 days.\n* Participants who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.\n* Participants who do not own a smartphone that meets the minimum technical requirements to run the survey app.\n* Employee of a company that manufactures tobacco or ENDS products.\n* Persons who are personally, have household members, or have close family or friends in litigation with a company that manufactures tobacco or ENDS products.\n* Have taken part in a tobacco\u002Fnicotine research study in the past 30 days.",true,"ALL","21 Years","65 Years",{"count":21,"type":22},1280,"ESTIMATED","INTERVENTIONAL",[25],"NA","The overall purpose of this study will be to assess primary combustible cigarette users' abstinence from smoking their usual brand of combustible cigarettes at the end of the study, when provided with an electronic nicotine delivery system (ENDS) power unit (2) and varying levels of access to tobacco-flavored, menthol-flavored, mint, or non-tobacco\u002Fnon-menthol\u002Fnon-mint-flavored cartridge-based e-liquids (collectively referred to as the investigational product) within their assigned study arm over a three-month (ninety-day) period.",[28,29],"Smoking","Tobacco",[31,28,32,33],"Tobacco Harm Reduction","Tobacco Use","Tobacco Smoking","RECRUITING","2026-06-01",{"date":37,"type":38},"2026-06-03","ACTUAL",{"date":40,"type":38},"2026-05-14",{"date":42,"type":22},"2027-01-21",{"name":44,"class":45},"RAI Services Company","INDUSTRY",7,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100635536","measuring-communal-coping-in-dual-smoking-couples-making-a-quit-attempt-100635536","NCT07553962","Measuring Communal Coping in Dual-smoking Couples Making a Quit Attempt","Communal Coping in Dual-Smoking Couples During a Quit Attempt","Inclusion Criteria:\n\n* Are over the age of 18\n* Smoke cigarettes on a daily basis\n* Smoke at least 5 cigarettes per day on average\n* Are in a committed relationship with an individual who smokes at least 5 cigarettes per day on average and is willing to participate in the study\n* Are willing to make a smoking cessation attempt at the time of enrollment into the study (applies to only one partner).","18 Years",{"count":56,"type":22},250,"OBSERVATIONAL","Smoking is the leading preventable cause of death in the United States, and quitting is especially difficult for couples who both smoke. When both partners smoke, they are less likely to quit successfully and more likely to relapse compared to people whose partner does not smoke. Research suggests that the way romantic partners interact and support each other during a quit attempt can make a real difference - but researchers do not yet know enough about what kinds of support actually help.\n\nThis study examines a concept called \"communal coping,\" which refers to when partners treat a shared health challenge - like quitting smoking - as something they are facing together as a team rather than as separate individuals. Researchers believe that couples who approach quitting this way may have better outcomes.\n\nTo study this, researchers will ask both members of dual-smoking couples to complete brief daily surveys over two weeks while making a quit attempt. These surveys will track how partners support (or discourage) each other's quitting efforts on a day-to-day basis, along with cigarette use, cravings, and stress. This will help researchers understand which relationship patterns are most helpful for quitting, and identify specific targets for future couples-based smoking cessation programs.",[60,61,29,62,63,64],"Smoking (Tobacco) Addiction","Smoking ( Cigarette)","Tobacco Abstinence","Quitting Smoking","Smoking Cessation",[66,67,68,69],"smoking cessation","tobacco","cigarette","relationships","2026-05-13",{"date":72,"type":38},"2026-05-15",{"date":74,"type":38},"2025-03-20",{"date":76,"type":22},"2026-12-01",{"name":78,"class":79},"University of Colorado, Denver","OTHER",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":80},"100580037","phase-4-combination-nicotine-replacement-therapy-cytisine-or-varenicline-for-smoking-cessation-100580037","NCT06832085","Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation","Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation: A Randomized Controlled Trial","CanQuit RCT","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Current cigarette smokers (more than 5 cigarettes per day) who are interested in reducing or quitting in the next 6 months.\n* Able to provide informed consent.\n* Living in Ontario, Canada\n\nExclusion Criteria:\n\n* Contraindications to any of the study medications (NRT, cytisine, varenicline).\n* Actively using one of the study medications in the past 7 days.\n* Actively enrolled in another formal smoking cessation program.\n* Pregnant or breastfeeding individuals.\n* Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).\n* Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).",{"count":90,"type":22},150,[92],"PHASE4","The purpose of this vanguard trial is to test whether clients of Sun Life are willing to join in a quit smoking program that offers counselling and tobacco cessation products to all participants over a 12-month period. The study team will track the safety and usage of 3 types of cessation products as well as the effectiveness of a virtual pharmacy (i.e. cessation products delivered to participants directly from a pharmacy). The goal is to recruit a minimum of 150 participants for this Vanguard phase.\n\nThe purpose of this study is to look at 3 approved smoking cessation products used in combination with counselling and virtual delivery of the smoking cessation products. The goal is to track product usage, safety, and adherence (how much of the products people use and how many counselling sessions they complete).\n\nWithin the study there will also be an observational group who will not receive study medication but who will receive free virtual coaching and follow-up for smoking cessation and complete study questionnaires.",[29],[29,96,97,98,99,100,101],"Tobacco cessation","Nicotine","Nicotine replacement therapy","Cytisine","Varenicline","counselling","2026-03-03",{"date":104,"type":38},"2026-03-05",{"date":106,"type":38},"2025-04-30",{"date":108,"type":22},"2027-10-30",{"name":110,"class":79},"Ottawa Heart Institute Research Corporation",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":128,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":80},"100618205","phase-4-impact-of-daridorexant-on-sleep-daytime-alertness-and-smoking-100618205","NCT07328594","Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking","Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking During Abstinence","INCLUSION\n\n1. Adult participants who are cigarette smokers, 18-55 years of age.\n2. Smokers: greater than 10 cigarettes\u002Fday.\n3. Smoking for 1 year or longer.\n4. Willingness to try to reduce or stay abstinent from cigarettes, smoking cessation aides (including nicotine gum or patches), smokeless tobacco, or electronic cigarettes for 3 weeks during the study.\n5. Willingness to monitor sleep at home with an external device and maintain a simple sleep and smoking diary for 3 weeks.\n6. Willingness to take a 5-min, mobile-based test 3X\u002Fday for 3 days\u002Fweek during the 3 weeks.\n7. Ability to travel to three Study Visits.\n8. Are willing to abstain from consuming grapefruit products during the study.\n9. Have an iPhone, best with iOS 17 or newer.\n\nEXCLUSION:\n\n1. Are currently taking any pharmaceutical drugs for smoking cessation, including: Nicotine patch or nicotine gum, buproprion (Wellbutrin, Zyban), varenicline (Chantix, Champix), other behavioral interventions such as cognitive behavioral therapy for smoking.\n2. Are currently using cannabis or alcohol for sleep. Are currently taking any pharmaceutical drugs for insomnia, such as eszopiclone (Lunesta), zaleplon (Sonata) or zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) benzodiazepines, or opioids.\n3. Are currently taking stimulants commonly used for ADHD, such as methylphenidate (Ritalin Concerta, Daytrana) or amphetamines (Adderall, Dexedrine, Vyvanse).\n4. Are currently taking anti-seizure drugs, including lamotrigine, pregabalin (Lyrica), or gabapentin (Neurontin, Horizant, or Gralise).\n5. Have non-nicotine substance dependence (diagnosed with substance use disorder, including alcohol or cannabis use disorder (current cannabis use is acceptable, and past illicit drug use is acceptable if greater than 2 months prior to testing and does not meet current criteria for substance use disorders (SUDs) according to DSM-5).\n6. Have a major neurological disorder such as Parkinson's disease, epilepsy, Alzheimer's disease, multiple sclerosis, or any other serious neurological disorder.\n7. Have a history of serious psychiatric disorders including bipolar disorder, schizophrenia, or suicidality.\n8. Had a stroke or head injury which caused loss of consciousness for longer than three minutes in the past 1 year.\n9. Are pregnant or breastfeeding.\n10. Have been diagnosed with sleep apnea or other diagnosed sleep disorders such as narcolepsy.\n11. Have been diagnosed with thyroid problems.\n12. Have been diagnosed with COPD.\n13. Have been doing variable shift work in the past 1 month or traveled more than 1 time zone in past month.\n14. Are currently taking the following medications, supplements, or food: Daridorexant can interact with strong inhibitors of CYP3A4, which should be discussed with The Study Doctor's office (some of these include clarithromycin, diltiazem, erythromycin, itraconzale, ketoconazole, ritonavir, and verapamil).\n15. Have a BMI of 33 or higher.","55 Years",{"count":120,"type":22},44,[92],"Tobacco use is the leading cause of preventable death in the U.S., with 480,000 deaths per year and 7.7 million deaths globally. A major clinical symptom associated with abstinence from both licit and illicit drugs is insomnia, which is a clinically verified, major risk factor for relapse. Roughly half of the 40 million smokers in the U.S. attempt to quit annually, with very low rates of success. One major hurdle is poor sleep quality during abstinence. Compounding the problem is that some pharmaceuticals to help reduce smoking can increase insomnia. Poor sleep is recognized as a major impediment to maintaining abstinence from several drugs of abuse, including nicotine. Blockers of orexin have recently been proposed as a promising therapy for smoking cessation. Insomnia has been reported in up to 40% of smokers, and 80% report regular sleep disturbances, which can be amplified during abstinence. A new orexin blocker, daridorexant, was FDA approved within the past two years for the treatment of insomnia, and while it has been tested in healthy individuals with insomnia, it has not been tested in smokers, who suffer from insomnia, particularly during the withdrawal phase when trying to quit. Daridorexant has an improved profile of beneficial effects for those with insomnia, the most notable advantage being its shorter duration of action that promotes daytime alertness, which is problematic for both active smokers and smokers during withdrawal. Poor sleep leads to daytime sleepiness, which often leads to smoking to maintain alertness.",[28,97,29,124,125,126,127],"Addiction","Substance Use Disorders","Insomnia","Sleep",[126,129,28,97,29,127,124,130],"Daridorexant","Substance use disorders","NOT_YET_RECRUITING","2026-01-07",{"date":134,"type":38},"2026-01-09",{"date":136,"type":22},"2026-02-10",{"date":138,"type":22},"2027-09-30",{"name":140,"class":79},"Legacy Health System",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":158,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":80},"100583958","quitting-matters-human-immunodeficiency-virus-hybrid-trial-100583958","NCT06883097","Quitting Matters Human Immunodeficiency Virus Hybrid Trial","Hybrid Trial of a Digital Therapeutic for Smoking Cessation Among Persons Living With HIV","QMH","Inclusion Criteria:\n\n1. Self-reported daily cigarette smoking over the past 30 days\n2. Self-reported HIV status\n3. Age 18 or older\n4. Desire to quit smoking\n5. Willing and medically eligible to use NRT\n6. Currently receiving HIV care\n7. Currently owning an Android or iOS smartphone\n\nExclusion Criteria:\n\n1. Current acute psychotic episode or unsafe to participate in the study\n2. Pregnant or intending to become pregnant in the next 6 months\n3. Currently receiving any pharmacological and\u002For behavioral intervention or counseling for smoking cessation\n4. Any medical condition or medication that could compromise subject safety, as determined by the PIs and\u002For study physician\n5. Not able to fluently speak and write in English\n6. Hearing, comprehension, visual, speech, or motor limitations that preclude study participation",{"count":150,"type":22},314,[25],"The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, they will also receive a combination of nicotine replacement therapy (patches and gums) that have been shown to help people quit smoking. The main questions this study aims to answer are:\n\nParticipants will complete 5 video call visits over about 6 months. Participants will install their assigned smoking cessation app onto their phone and will be asked to use the app for the duration of the study along with their provided Nicotine Replacement Therapy (NRT) products. During the study visits, participants will meet with study staff to complete questionnaires and interviews. Participants may be asked to provide breath and saliva samples to measure the level of carbon monoxide and nicotine.",[29,62,64,154,155,156,157],"Smoking Cessation; Tobacco Dependence","Human Immunodeficiency Virus (HIV)","Tobacco Dependence Caused by Cigarettes","Cancer Prevention",[29,64,159,62,160],"Human immunodeficiency virus (HIV)","Quit Smoking","2025-12-15",{"date":163,"type":38},"2025-12-17",{"date":165,"type":38},"2025-08-18",{"date":167,"type":22},"2028-12",{"name":169,"class":79},"Wake Forest University Health Sciences",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":188,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":80},"100603330","targeting-lifestyle-to-improve-colorectal-cancer-screening-100603330","NCT07135115","Targeting Lifestyle to Improve Colorectal Cancer Screening","KoloPrev","Inclusion Criteria:\n\n* Invited to the first round of immunochemical faecal blood testing in the national colorectal cancer screening program via a digital platform.\n\nExclusion Criteria:\n\n* Not invited to the national colorectal cancer screening program.","56 Years",{"count":179,"type":22},16000,[25],"The goal of this study is to learn whether receiving personalized, digital lifestyle advice during colorectal cancer screening leeds to changes in lifestyle over a two-year follow-up period. Changes will be measured using a composite score including diet, alcohol consumption, physical activity, body mass index and smoking habits. The main questions it aims to answer are:\n\n* Do participants who receive short, personalized digital feedback on their lifestyle - either once or through repeated rounds -change their lifestyle during the two-year study period, compared to those who do not receive any feedback?\n* Does the inclusion of additional contact, such as telephone consultation with healthcare providers, result in further lifestyle changes?\n\nResearchers will compare three groups which receive digital feedback at different intensities and a control group which does not get any feedback to see if lifestyle changes differ between the groups.\n\nParticipants in four different groups will fill in a digital diet and lifestyle questionnaire at the start of the study and 2-4 times after this during the following 2 years.\n\n* Participants in three of the groups will receive a short digital feedback report on their lifestyle related to health recommendations after each completion of the questionnaire.\n* One of these groups will also be offered to go through the feedback report together with a healthcare provider in a telephone call.\n* This group will also receive invitations to motivational webinars every half year during the 2-year study period. The topics in the webinars address cancer preventive lifestyle.\n\nA secondary goal of the study is to understand whether the invitation to fill in the diet and lifestyle questionnaire affects participation in colorectal cancer screening. Therefore, a fifth group of individuals invited to colorectal cancer screening but not to be invited to fill in the questionnaire will be included for extra comparison. Participation in colorectal cancer screening will be compared between this group and the four groups that are additionally invited to complete the questionnaire.\n\nAnother secondary goal is to learn which groups in the society consent to the current study. Therefore, sociodemographic characteristics will be compared between the invited individuals who consent and those who do not consent to the study.",[183,29,184,185,186,187],"Lifestyle Alteration","Diet Modification","Physical Activity","Alcohol Consumption","Body Weight Control",[189,190,191,192,28,193,194,195],"Lifestyle intervention","Colorectal cancer screening","Diet","Alcohol consumption","Body mass index","Physical activity","Digital questionnaire","2025-08-26",{"date":198,"type":38},"2025-09-03",{"date":200,"type":22},"2025-10-15",{"date":202,"type":22},"2041-12-31",{"name":204,"class":205},"Norwegian Institute of Public Health","OTHER_GOV"]